LVTX — LAVA Therapeutics NV Share Price
0.000.00%
Last trade - 00:00- $71.24m
- -$18.01m
- $6.77m
- 33
- 13
- 87
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.39 | ||
| Price to Tang. Book | 1.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.85% | ||
| Return on Equity | -61.18% | ||
| Operating Margin | -638.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3.5 | 5 | 19.39 | 6.77 | 7.01 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 15th, 2016
- Public Since
- March 29th, 2021
- No. of Employees
- 37
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 26,289,087
- Address
- Yalelaan 60, UTRECHT, 3584 CM
- Web
- https://www.lavatherapeutics.com/
- Phone
- +31 30003035
- Auditors
- PricewaterhouseCoopers Accountants N.V.
Upcoming Events for LVTX
LAVA Therapeutics NV Annual Shareholders Meeting
Q2 2024 LAVA Therapeutics NV Earnings Release
Similar to LVTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the LAVA Therapeutics NV share price?
As of Today at 19:13 UTC, shares in LAVA Therapeutics NV are trading at $2.71. This share price information is delayed by 15 minutes.
How has the LAVA Therapeutics NV share price performed this year?
Shares in LAVA Therapeutics NV last closed at $2.71 and the price had moved by +66.26% over the past 365 days. In terms of relative price strength the LAVA Therapeutics NV share price has outperformed the S&P500 Index by +38.35% over the past year.
What are the analyst and broker recommendations for LAVA Therapeutics NV?
The overall consensus recommendation for LAVA Therapeutics NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the LAVA Therapeutics NV dividend yield?
LAVA Therapeutics NV does not currently pay a dividend.
Does LAVA Therapeutics NV pay a dividend?
LAVA Therapeutics NV does not currently pay a dividend.
When does LAVA Therapeutics NV next pay dividends?
LAVA Therapeutics NV does not currently pay a dividend.
How do I buy LAVA Therapeutics NV shares?
To buy shares in LAVA Therapeutics NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LAVA Therapeutics NV?
As of the previous close price of $2.71, shares in LAVA Therapeutics NV had a market capitalisation of $71.24m.
Where are LAVA Therapeutics NV shares listed?
Here are the trading details for LAVA Therapeutics NV:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LVTX
What kind of share is LAVA Therapeutics NV?
Based on an overall assessment of its quality, value and momentum LAVA Therapeutics NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LAVA Therapeutics NV share price forecast for 2024?
The analyst consensus target price for shares in LAVA Therapeutics NV is $6.81. That is 151.19% above the last closing price of $2.71.
Analysts covering LAVA Therapeutics NV currently have a consensus Earnings Per Share (EPS) forecast of -$1.51 for the next financial year.
What is the trend in the LAVA Therapeutics NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LAVA Therapeutics NV. Over the past six months, its share price has outperformed the S&P500 Index by +70.42%.
As of the last closing price of $2.71, shares in LAVA Therapeutics NV were trading +43.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LAVA Therapeutics NV PE Ratio?
The LAVA Therapeutics NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LAVA Therapeutics NV?
We do not have data on LAVA Therapeutics NV's directors